Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda.
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Department of Neurosurgery, The Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
J Neurosurg. 2012 Dec;117(6):1022-1031. doi: 10.3171/2012.9.JNS1212. Epub 2012 Oct 12.
Tumor-initiating cells are uniquely resilient to current treatment modalities and play an important role in tumor resistance and recurrence. The lack of specific tumor-initiating cell markers to identify and target these cells presents a major obstacle to effective directed therapy.
To identify tumor-initiating cell markers in primary brain tumors, the authors compared the proteomes of glioma tumor-initiating cells to their differentiated progeny using a novel, nongel/shotgun-based, multidimensional liquid-chromatography protein separation technique. An in vivo xenograft model was used to demonstrate the tumorigenic and stem cell properties of these cells. Western blot and immunofluorescence analyses were used to confirm findings of upregulated ciliary neurotrophic factor receptor subunit-α (CNTFRα) in undifferentiated tumor-initiating cells and gliomas of increasing tumor grade. Sequencing of the CNTFRα coding regions was performed for mutation analysis. Finally, antibody-dependent cell-mediated cytotoxicity was used to establish the role of CNTFRα as a potential immunotherapeutic target.
Ciliary neurotrophic factor receptor subunit-α expression was increased in tumor-initiating cells and was decreased in the cells' differentiated progeny, and expression levels increased with glioma grade. Mutations of CNTFRα are not common in gliomas. Functional studies using CNTF treatment in glioma tumor-initiating cells showed induction of differentiation through the CNTFRα pathway. Treatment with anti-CNTFRα antibody resulted in increased antibody-dependent cell-mediated cytotoxicity in CNTFRα expressing DAOY cells but not in cell lines that lack CNTFRα.
These data indicate that CNTFRα plays a role in the formation or maintenance of tumor-initiating cells in gliomas, is a marker that correlates with histological grade, may underlie treatment resistance in some cases, and is a potential therapeutic target.
肿瘤起始细胞对当前的治疗方式具有独特的抵抗力,并且在肿瘤耐药和复发中发挥着重要作用。缺乏用于识别和靶向这些细胞的特异性肿瘤起始细胞标志物,这是有效靶向治疗的主要障碍。
为了鉴定原发性脑肿瘤中的肿瘤起始细胞标志物,作者使用一种新的、不依赖凝胶/无胶束的多维液相色谱蛋白质分离技术,比较了神经胶质瘤肿瘤起始细胞与其分化后代的蛋白质组。使用体内异种移植模型来证明这些细胞的致瘤性和干细胞特性。Western blot 和免疫荧光分析用于确认未分化的肿瘤起始细胞和肿瘤分级增加的神经胶质瘤中 CNTFRα 上调的发现。对 CNTFRα 编码区进行测序以进行突变分析。最后,抗体依赖性细胞介导的细胞毒性用于确定 CNTFRα 作为潜在免疫治疗靶标的作用。
神经睫状神经营养因子受体亚基-α(CNTFRα)在肿瘤起始细胞中的表达增加,在其分化后代中的表达减少,并且表达水平随着神经胶质瘤分级的增加而增加。CNTFRα 中的突变在神经胶质瘤中并不常见。使用 CNTF 治疗神经胶质瘤肿瘤起始细胞的功能研究表明,通过 CNTFRα 途径诱导分化。用抗 CNTFRα 抗体处理表达 CNTFRα 的 DAOY 细胞会导致抗体依赖性细胞介导的细胞毒性增加,但缺乏 CNTFRα 的细胞系则没有。
这些数据表明,CNTFRα 在神经胶质瘤中的肿瘤起始细胞的形成或维持中发挥作用,是与组织学分级相关的标志物,在某些情况下可能是治疗耐药的基础,并且是潜在的治疗靶标。